Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options

American Health and Drug Benefits

Volumn 7, Issue 2, 2014, Pages 71-81

  Sylwestrzak, Gosia ^a   Liu, Jinan ^a   Stephenson, Judith J ^a   Ruggieri, Alexander P ^b   DeVries, Andrea ^a  

^a HEALTHCORE INC   (United States)

^b Wellpoint Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; CHRONIC ARTHRITIS; CROSS-SECTIONAL STUDY; DRUG ADMINISTRATION ROUTE; FEMALE; HUMAN; INFLAMMATORY DISEASE; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; PATIENT PREFERENCE; PATIENT SATISFACTION; PSORIASIS VULGARIS; QUESTIONNAIRE; VERY ELDERLY;

EID: 84899837071     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. King S. The best selling drugs of all time; Humira joins the elite. Pharma & Healthcare. Forbes. January 28, 2013. www.forbes.com/sites/simonking/2013/01/28/the-best-selling-drugs-of-all-time-humira-joins-the-elite/. Accessed January 28, 2014.
2. Phillips DJ. After top-seller Remicade: analysis of J&J's future. YCharts Analysis. December 3, 2013. http://ycharts.com/analysis/story/after_topseller_remicade_analysis_ of_jandjs_future. Accessed January 28, 2014.
3. Zorzi F, Zuzzi S, Onali S, et al. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study. Aliment Pharmacol Ther. 2012;35:1397-1407.
4. Kestens C, van Oijen MG, Mulder CL, et al; for the Dutch Initiative on Crohn and Colitis (ICC). Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents. Clin Gastroenterol Hepatol. 2013;11:826-831.
5. Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339-353.
6. Atteno M, Peluso R, Costa L, et al. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol. 2010;29:399-403.
7. US Food and Drug Administration. Information on tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm109340.htm. Accessed March 27, 2014.
8. Remicade (infliximab) [prescribing information]. Horsham, PA: Janssen Biotech; November 2013.
9. Enbrel (etanercept) solution [prescribing information]. Thousand Oaks, CA: Immunex Corporation; 2013.
10. Humira (adalimumab) injection [prescribing information]. North Chicago, IL: Abbott Laboratories; September 2013.
11. Simponi (golimumab) injection [prescribing information]. Horsham, PA: Janssen Biotech, Inc; November 2013.
12. Cimzia (certolizumab pegol) injection [prescribing information]. Smyrna, GA: UCB, Inc; 2013.
13. Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care. 2008;6:1-14.
14. Williams EL, Edwards CJ. Patient preferences in choosing anti-TNF therapies-R1. Letter. Rheumatology (Oxford). 2006;45:1575-1576.
15. Scarpato S, Antivalle M, Favalli EG, et al; for the RIVIERA co-authors. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford). 2010;49:289-294.
16. Huynh TK, Østergaard A, Egsmose C, Madsen OR. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence. 2014;8:93-99.
17. Pitchumoni S, Scherl EJ, Bosworth BP, et al. Patient preferences for subcutaneous versus intravenous formulations of anti-TNF agents for treatment of inflammatory bowel disease. Gastroenterology. 2008;134(4 suppl 1). Abstract W1242.
18. Allen IE, Seaman CA. Statistics roundtable: Likert scales and data analyses. Qual Prog. 2007;40:64-65.
19. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health. 2005;8(suppl 1):S9-S24.
20. Greenapple R. Trends in biologic therapies for rheumatoid arthritis: results from a survey of payers and providers. Am Health Drug Benefits. 2012;5(2):83-92.
21. Zhang J, Xie F, Delzell E, et al. Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US Medicare program. Arthritis Care Res. 2013;65:1743-1751.
22. Polinski JM, Mohr PE, Johnson L. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis. Arthritis Rheum. 2009;61:745-754.
23. DeVries A, Liu J, Sylwestrzak G, Ruggieri A. Comparison of cost sharing for anti-TNF agents in a commercially insured Crohn's disease population. J Manag Care Pharm. 2014;20(4-a suppl). Abstract K2.
24. Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis. 2013;19:1528-1533.